Johns Hopkins to ban gifts, drug samples

Share this article:

Johns Hopkins announced the approval of a policy that will severely limit industry interaction with its school of medicine.

Industry-funded meals, drug samples and gifts to individuals will be off limits to Johns Hopkins faculty and staff under the policy, effective July 1, 2009. The drug sample provision will become effective next year – on July 1, 2010 – so that “affected providers and clinics can make the needed changes,” according to the policy.

“Gifts, even small gifts, carry an implied expectation of reciprocity,” the policy stated. “Accepting a coffee mug or mouse pad from a pharmaceutical sales representative may not consciously affect one's decision-making,” but the presence of the gift, or the interaction with the giver, could cloud a physician's judgment, the policy concluded, citing research from the Annual Review of Neuroscience.

The policy makes an exception for certain unrestricted gifts, which are deposited into a departmental account and distributed at the school's discretion. Departments will be required to report all funds received from industry, and how those funds were spent, the policy stated.

Johns Hopkins' gift ban follows similar initiatives at several other academic institutions, including Stanford and the University of Pittsburgh. The University of Minnesota is currently reviewing a comparable policy.

Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

More in News

New lipid agents are high on potency, low on doc awareness

New lipid agents are high on potency, low ...

The new PCSK9 class of cholesterol-lowering antibodies continues to look promising, but many doctors—particularly PCPs—have never even heard of the experimental drugs.

Novartis may have game-changing drug

Novartis may have game-changing drug

Key opinion leaders indicate they are ready to embrace Novartis's experimental heart failure medication LCZ696. Such a move could upend heart failure treatment protocols.

Five things for pharma marketers to know: Tuesday, September 2

Five things for pharma marketers to know: Tuesday, ...

Sanofi and Regeneron unveil Phase-III results of their PCSK9; Merck will present data on its anti-PD-1 at the end of this month; WSJ op/ed suggests US should lead fight against ...